Valuation: Zai Lab Limited

Market Cap 2.16B 16.93B 1.9B 1.76B 1.62B 3.04B 208B 3.09B 20.95B 8.18B 102B 8.11B 7.93B 353B P/E 2026 *
-8.68x
P/E 2027 * -10.3x
Enterprise Value 1.72B 13.46B 1.51B 1.4B 1.29B 2.42B 165B 2.45B 16.65B 6.5B 81.26B 6.44B 6.3B 281B EV / Sales 2026 *
3.83x
EV / Sales 2027 * 2.98x
Free-Float
95.17%
Yield 2026 *
-
Yield 2027 * -
1 day-4.05%
1 week-0.77%
Current month+6.36%
1 month+8.39%
3 months-12.66%
6 months+7.78%
Current year+12.67%
1 week 15.21
Extreme 15.21
16.5
1 month 13.62
Extreme 13.62
16.5
Current year 12.31
Extreme 12.31
20.42
1 year 12.31
Extreme 12.31
32.35
3 years 10.56
Extreme 10.56
35.5
5 years 10.56
Extreme 10.56
120
10 years 10.56
Extreme 10.56
151.2
Manager TitleAgeSince
Chief Executive Officer 61 2014-03-31
Director of Finance/CFO 58 2023-07-06
President 62 2022-11-30
Director TitleAgeSince
Chairman 61 2014-03-31
Director/Board Member 83 2016-12-31
Director/Board Member 75 2016-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-4.05%-0.77% - - 2.16B
+0.63%-3.06%+16.18%-9.78% 66.74B
+1.23%+2.80%+37.51%+202.14% 53.32B
+10.08%+51.80%+51.80%+51.80% 48.12B
-1.32%-7.38%-57.63%-57.10% 38.25B
+0.78%-1.84%+52.49%-27.01% 29.85B
+0.84%+0.36%+66.93%+85.42% 23.51B
-5.17%-12.54%+58.98%-56.04% 21.45B
-1.21%+1.12%+1.98%+170.93% 19.97B
-0.22%-0.95%+61.97%+123.78% 16.38B
Average +0.76%+0.04%+32.25%+53.79% 35.29B
Weighted average by Cap. +1.77%+0.76%+27.80%+49.98%

Financials

2026 *2027 *
Net sales 449M 3.52B 394M 366M 336M 632M 43.21B 642M 4.35B 1.7B 21.24B 1.68B 1.65B 73.45B 596M 4.67B 523M 486M 446M 839M 57.35B 852M 5.78B 2.26B 28.2B 2.24B 2.19B 97.49B
Net income -241M -1.89B -212M -197M -181M -339M -23.2B -344M -2.34B -913M -11.41B -904M -885M -39.43B -156M -1.23B -137M -128M -117M -220M -15.07B -224M -1.52B -593M -7.41B -587M -575M -25.61B
Net Debt -443M -3.48B -389M -362M -332M -624M -42.67B -634M -4.3B -1.68B -20.98B -1.66B -1.63B -72.54B -387M -3.04B -340M -316M -290M -545M -37.29B -554M -3.76B -1.47B -18.33B -1.45B -1.42B -63.38B
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
1,784
Date Price Change Volume
26-07-24 HK$15.38 -4.05% 4,724,300
26-07-23 HK$16.03 -0.56% 2,402,350
26-07-22 HK$16.12 +1.26% 4,966,152
26-07-21 HK$15.92 -1.00% 3,591,400
26-07-20 HK$16.08 +3.74% 5,697,655
Trader
Investor
-
Global
-
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
19.22USD
Average target price
33.30USD
Spread / Average Target
+73.27%

Quarterly revenue - Rate of surprise